RZLT at a glance
Rezolute, Inc. (RZLT, SEC CIK 1509261) filed its latest 10-K annual report on September 24, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as October 23, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Rezolute, Inc. (RZLT) shares worth $101.7 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Evans Daron on March 30, 2026 of 10,000 shares at $2.85 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 23 funds
- $101.7M · −4 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 7.01 · Item 1.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Jun 30, 2026
Management Discussion & Analysis
- Revenue nil for 2026 and 2025; no commercial products, no meaningful revenue since inception
- Net loss $77.6M in 2026 vs $74.4M in 2025; operating expenses increased 4% to $83.0M; R&D down 13% to $53.8M; G&A up 59% to $29.2M
- Best performing: R&D expenses down $7.7M (mainly $9.3M manufacturing cost reduction); worst performing: G&A expenses up $10.8M driven by $5.7M compensation and $4.6M business development costs
- Cash & equivalents $10.6M, marketable securities $97.2M; operating cash outflow $64.6M; investing cash outflow $21.1M; financing inflow only $2.3M in 2026 (vs $107.3M in 2025 from equity financings)
- Management expects sufficient capital for 12 months; key near-term events include upLIFT Phase 3 topline data in 2026, FDA review of sunRIZE data ongoing with no timeline, and potential BLA submission mid-2027 for ersodetug
Business Overview
- Core business: Late-stage rare disease company developing therapies for refractory hypoglycemia caused by various hyperinsulinism forms
- New emphasis: Phase 3 results for ersodetug in congenital HI showed significant CGM-based hypoglycemia improvements despite missing primary endpoint
- Strategic update: FDA review ongoing uniquely outside formal meetings, with encouragement to submit comprehensive data for regulatory path determination
- Quantitative highlight: R&D expense $53.8M in 2026 down from $61.5M in prior year; 58 full-time employees, all US-based
- Noteworthy fact: Six of eight participants met primary endpoint in ongoing Phase 3 tumor HI trial, with notable discontinuation of intravenous glucose
Risk Factors
- Regulatory risk: FDA review of supplemental data for ersodetug post-sunRIZE trial may require a new randomized study, delaying commercialization
- Macroeconomic risk: Potential supply chain delays and cost increases due to inflation, tariffs, and global conflicts impacting raw material availability
- Supply chain risk: Dependence on a limited number of third-party suppliers with no commercial production agreements for raw materials and drug manufacturing
- Competitive risk: Equity investigations and stock price decline following sunRIZE trial failure may hurt financing and competitive positioning
- Financial risk: Net losses $77.6M FY26, $74.4M FY25 with only $10.6M cash and $97.2M debt securities, requiring additional capital within 12 months to sustain operations
AI summary of the RZLT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added regulatory risk: FDA pre-BLA recommendation may not support ersodetug approval for congenital HI
- Clinical-development risk: FDA could require another sunRIZE-like study, delaying BLA submission and increasing costs
- Newly added trial risk: Phase 3 upLIFT topline results expected December 2026 may fail to meet endpoints for tumor HI approval
- Carried-forward risks: 2026 Form 10-K risk factors otherwise unchanged materially
Management Discussion & Analysis
- Revenue $0 for Q3 2026, unchanged from $0 in Q3 2025
- Net loss $18.5M vs $18.2M YoY, no operating margin disclosed
- Tumor HI upLIFT: 7 of first 8 participants met responder criteria, all discontinued intravenous glucose
- Cash and investments $90.0M at September 30, 2026, sufficient for at least 12 months
- Operating cash outflow $18.8M vs $17.4M YoY, with $15.8M investing cash inflow
AI summary of the RZLT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Pricing press release announces terms of Rezolute’s Offering, creating potential dilution or added financing resources
- Investors should review Exhibit 99.1 for offering size, security type, price, and expected use of proceeds
Item 1.01: Entry into a Material Definitive Agreement
- $93.5M estimated net proceeds from equity offering, strengthening funding for ersodetug commercialization preparation and working capital
- 22,040,976 shares priced at $3.8700 plus pre-funded warrants for 3,800,000 shares priced at $3.8690
Item EX-99.1: Item EX-99.1
- Approximately $100 million gross equity financing, strengthening funding for ersodetug commercialization preparation and working capital
- 22,040,976 common shares priced at $3.87 each, creating substantial dilution for existing shareholders
Item 8.01: Other Events
- Item 8.01 incorporates most of the Item 7.01 press release into the filing
- Investor significance depends on the underlying announcement in the referenced press release
Item 7.01: Regulation FD Disclosure
- November 13, 2026 press release announces an interim update on Rezolute’s upLIFT study
- Study update represents potentially material clinical-development information for Rezolute investors
Item EX-99.1: Item EX-99.1
- Phase 3 upLIFT primary endpoint achieved: 13 of 16 participants met the required 50% GIR reduction
- 12 responders completely discontinued IV glucose, strengthening ersodetug’s potential clinical benefit in tumor hyperinsulinism
Item 2.02: Results of Operations and Financial Condition
- Rezolute announced financial results for Q1 ended September 30, 2026
- Full financial figures and management commentary are in Exhibit 99.1, the attached earnings release
Item EX-99.1: Item EX-99.1
- Cash, equivalents and marketable investments $90.0M, down from $107.8M, highlighting continued financing needs
- Net loss $18.5M, or $0.18 per share, versus $18.2M and $0.18 in the prior-year quarter
AI summaries of RZLT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RZLT
Don't miss the next RZLT filing
- Alerts as it files. A push when RZLT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RZLT, by share count.
- Ask anything. An AI agent that reads every RZLT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Evans Daron | G | Oct 21, 2026 | 4,000 | - |
| Evans Daron | G | Oct 21, 2026 | 4,000 | - |
| Evans Daron | G | Oct 21, 2026 | 16,000 | - |
| Karnawat Sunil Ratilal | F | Sep 2, 2026 | 2,267 | $4.50 |
| Evans Daron | F | Jul 2, 2026 | 3,062 | $4.99 |
| ROBERTS BRIAN KENNETH | F | Jul 2, 2026 | 3,062 | $4.99 |
| Elam Nevan C | F | Jul 2, 2026 | 8,004 | $4.99 |
| Evans Daron | Buy | Mar 30, 2026 | 10,000 | $2.85 |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | -$70.4M | -$79.9M | -$83.0M | |
| Net Income | -$68.5M | -$74.4M | -$77.6M | |
| Balance Sheet | ||||
| Total Assets | $132.7M | $175.5M | $112.8M | |
| Equity | $121.0M | $162.1M | $100.7M | |
| ROE | -56.6% | -45.9% | -77.1% | |
| Per Share | ||||
| EPS | $-1.33 | $-0.98 | $-0.75 | |
| Cash Flow | ||||
| Operating CF | -$57.4M | -$69.1M | -$64.6M | |
Source: XBRL data in Rezolute, Inc. (RZLT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate RZLT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 23 | $101.7M |
| Q2 2026 | 27 | $134.8M |
| Q1 2026 | 25 | $84.4M |
| Q4 2025 | 23 | $71.9M |
| Q3 2025 | 23 | $324.5M |
| Q2 2025 | 21 | $131.3M |
| Q1 2025 | 13 | $38.9M |
| Q4 2024 | 10 | $25.9M |
- Millennium Management+838.4K (+162%)
- BlackRock+553.4K (+7%)
- D.E. Shaw & Co+549.6K (+30%)
- Citadel Advisors LLC+485.6K (+493%)
- Two Sigma Investments+280.4K (+65%)
- Morgan Stanley−1.33M (-82%)
- Bank of America Corp−624.8K (-86%)
- Goldman Sachs Group−430.4K (-33%)
- Vanguard Capital Management LLC−117.5K (-3%)
- Vanguard Portfolio Management LLC−101.3K (-7%)
- Blackstone Group−1.08M
- FMR LLC (Fidelity)−216.1K
- Franklin Resources−104.7K
- Ameriprise Financial−97.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 165 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RZLT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 8-K | Nov 13, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 4 | Oct 23, 2026 | - | - | - |
| 8-K | Oct 14, 2026 | - | Analysis | - |
| 8-K | Oct 5, 2026 | - | Analysis | - |
| 8-K | Sep 24, 2026 | - | Analysis | - |
| 10-K | Sep 24, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Sep 3, 2026 | - | - | - |
| SC 13G | Aug 12, 2026 | - | - | |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jul 7, 2026 | - | - | - |
| 8-K | Jun 2, 2026 | - | Analysis | |
| SC 13G | May 15, 2026 | - | - | |
| 8-K | May 12, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 4 | Mar 31, 2026 | - | - | - |
| 8-K | Mar 24, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
RZLT SEC filings: frequently asked questions
Which institutions hold RZLT stock?
As of September 30, 2026, the largest Rezolute, Inc. (RZLT) holders among the 13F filers tracked by SignalX were BlackRock ($34.2 million), Vanguard Capital Management LLC ($15.4 million), D.E. Shaw & Co ($9.9 million), State Street Corp ($7.6 million), Millennium Management ($5.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in RZLT's latest 10-K?
In the 10-K filed September 24, 2026, Rezolute, Inc. (RZLT) flagged: Regulatory risk: FDA review of supplemental data for ersodetug post-sunRIZE trial may require a new randomized study, delaying commercialization. Macroeconomic risk: Potential supply chain delays and cost increases due to inflation, tariffs, and global conflicts impacting raw material availability. (AI summary of the Risk Factors section.)
What did RZLT report in its latest 8-K?
Rezolute, Inc. (RZLT) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 1.01 (Entry into a Material Definitive Agreement). Pricing press release announces terms of Rezolute’s Offering, creating potential dilution or added financing resources.
What are the latest RZLT SEC filings?
Rezolute, Inc. (RZLT) filed its latest 10-K annual report on September 24, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on October 23, 2026.
What is RZLT's SEC CIK number?
Rezolute, Inc. (RZLT)'s SEC Central Index Key (CIK) is 1509261. EDGAR lists every RZLT filing under that number.
Ask anything about RZLT
The research agent reads RZLT's filings, financials, insider trades and 13F holders, then answers with sources.